Winton Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-291,360
Closed 1563
2021
Q3
$0 Hold
291,360
﹤0.01% 1538
2021
Q2
$0 Hold
291,360
﹤0.01% 1568
2021
Q1
$0 Hold
291,360
﹤0.01% 1493
2020
Q4
$720K Sell
291,360
-283,063
-49% -$689K 0.05% 594
2020
Q3
$1.81M Sell
574,423
-268,527
-32% -$858K 0.06% 572
2020
Q2
$2.45M Buy
842,950
+205,639
+32% +$650K 0.06% 551
2020
Q1
$1.8M Sell
637,311
-1,306,463
-67% -$4.21M 0.05% 607
2019
Q4
$6.31M Buy
1,943,774
+369,994
+24% +$1.07M 0.09% 396
2019
Q3
$3.4M Buy
1,573,780
+186,895
+13% +$500K 0.04% 409
2019
Q2
$4.36M Buy
1,386,885
+51,942
+4% +$168K 0.08% 222
2019
Q1
$4.97M Buy
+1,334,943
New +$4.51M 0.1% 245

Winton Group's PDLI Position: Q4 2021 in Review

Winton Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2021, closing a stake of 291,360 shares.

Winton Group first reported a position in PDLI in Q1 2019 and held it in 11 quarters. The position peaked at $6.31M in Q4 2019. 5 funds tracked by Wall St. Rank hold PDLI as of Q4 2021.

  • Winton Group reported no remaining PDL BioPharma, Inc. position as of Q4 2021 after selling out during the quarter.
  • Winton Group sold 291,360 PDL BioPharma, Inc. shares in Q4 2021.
  • Winton Group first reported a position in PDL BioPharma, Inc. in Q1 2019 and held it in 11 quarters.
  • Winton Group's PDL BioPharma, Inc. position peaked at $6.31M in Q4 2019.
  • 5 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.